8-K: Amylyx's Phase 3 PHOENIX Trial Fails to Meet Primary Endpoint, Future of ALS Drug in Question

Amylyx Pharmaceuticals' Phase 3 PHOENIX trial for AMX0035 in ALS did not meet its primary endpoint, leading to a potential market withdrawal of the drug.

Summary

• Amylyx Pharmaceuticals announced that its global Phase 3 PHOENIX trial for AMX0035 in ALS did not meet its primary endpoint, which was to show a statistically significant change in the ALSFRS-R score at week 48.
• The trial, which included 664 participants, also did not show statistical significance in secondary endpoints.
• The company is now considering voluntarily withdrawing RELYVRIO/ALBRIOZA from the market, but the drug will remain available for patients for the time being.
• Amylyx has paused promotion of the drug while they engage with regulatory authorities and the ALS community to discuss the results.
• The company is continuing its studies of AMX0035 in other neurodegenerative diseases, including ongoing Phase 3 trials for Progressive Supranuclear Palsy (PSP) and Phase 2 trials for Wolfram syndrome.

Sentiment

Score: 3

Explanation: The document conveys a negative sentiment due to the failure of the Phase 3 trial and the potential market withdrawal of the drug. While the company expresses commitment to the ALS community, the overall tone is one of disappointment and uncertainty.

Positives

• AMX0035 was shown to be generally safe and well-tolerated in the PHOENIX trial.
• The company is continuing to study AMX0035 in other neurodegenerative diseases, including PSP and Wolfram syndrome.
• The ongoing HELIOS study is showing evidence of clinical activity of AMX0035 in Wolfram syndrome.
• RELYVRIO/ALBRIOZA will remain available for people living with ALS while the company engages with regulatory authorities.

Negatives

• The PHOENIX trial failed to meet its primary endpoint, indicating the drug did not show a statistically significant benefit for ALS patients.
• There was no statistical significance observed in any secondary endpoints of the PHOENIX trial.
• Amylyx is considering voluntarily withdrawing RELYVRIO/ALBRIOZA from the market.
• The company has paused promotion of RELYVRIO/ALBRIOZA.

Risks

• The failure of the PHOENIX trial could lead to a loss of confidence in AMX0035's efficacy in ALS.
• The potential withdrawal of RELYVRIO/ALBRIOZA from the market could impact revenue and future growth.
• There is a risk that ongoing studies in other neurodegenerative diseases may not yield positive results.
• Regulatory authorities may require additional data or studies before approving AMX0035 for other indications.

Future Outlook

Amylyx will engage with regulatory authorities and the ALS community to discuss the PHOENIX trial results and make informed decisions about the future of RELYVRIO/ALBRIOZA, which may include a voluntary market withdrawal. The company will continue to evaluate AMX0035 in other neurodegenerative diseases, with data readouts expected in the ORION and HELIOS studies.

Management Comments

• We are surprised and deeply disappointed by the PHOENIX results following the positive data from the CENTAUR trial.
• Our main priority at the moment is sharing the information with people living with ALS and their treating physicians.
• We will be led in our decisions by two key principles: doing what is right for people living with ALS, informed by regulatory authorities and the ALS community, and by what the science tells us.
• With data collected from 664 participants in PHOENIX, we are certain there will be important learnings that will help inform future ALS research.
• We are steadfast in our commitment to the ALS community and our mission, including with AMX0035 where it has shown potential in neurodegenerative diseases such as Wolfram syndrome and progressive supranuclear palsy, and with AMX0114, our investigational antisense oligonucleotide targeting calpain-2, in ALS.

Industry Context

The failure of the PHOENIX trial highlights the challenges in developing effective treatments for ALS, a complex and rapidly progressing neurodegenerative disease. The results may impact investor sentiment towards other companies developing ALS therapies. The company's decision to pause promotion and consider market withdrawal of RELYVRIO/ALBRIOZA could set a precedent for other companies facing similar challenges.

Comparison to Industry Standards

• The failure of the PHOENIX trial contrasts with the positive results from the earlier CENTAUR trial, which had shown a reduction in functional decline as measured by the ALSFRS-R.
• Other companies developing ALS treatments, such as Biogen with Tofersen, have also faced challenges in clinical trials, highlighting the difficulty in finding effective therapies for this disease.
• The PHOENIX trial's results are a setback compared to the industry's hope for a disease-modifying treatment for ALS, as many trials have failed to meet their primary endpoints.
• The company's decision to consider market withdrawal is a significant step, as many companies often try to continue marketing drugs even with marginal results.

Stakeholder Impact

• Shareholders may experience a negative impact due to the failed trial and potential market withdrawal.
• Patients with ALS may face uncertainty regarding the availability of RELYVRIO/ALBRIOZA.
• Employees of Amylyx may experience uncertainty about the company's future direction.
• The broader ALS community may be disappointed by the trial results, but the data will inform future research.

Next Steps

• Amylyx will engage with regulatory authorities and the ALS community to discuss the PHOENIX trial results within the next eight weeks.
• The company will make informed decisions about the future of RELYVRIO/ALBRIOZA, which may include a voluntary market withdrawal.
• Amylyx plans to present the data from PHOENIX at an upcoming medical meeting and will publish the results in a medical journal later this year.
• The company will continue to evaluate AMX0035 in other neurodegenerative diseases, including the ongoing ORION and HELIOS studies.
• An interim analysis is planned for the ORION study.
• Preliminary data from the HELIOS study is expected in the second quarter of 2024.

Key Dates

Keywords

ALS, AMX0035, RELYVRIO, ALBRIOZA, PHOENIX Trial, Neurodegenerative Diseases, Clinical Trial, Amylyx Pharmaceuticals, PSP, Wolfram Syndrome